Thyroid Metastases from Triple-Negative Breast Cancer with High PD-L1 Expression – A Rare Presentation
Wenjuan Meng,Qingxia Guo,Gaoyan Tang,Guiyan Han,Guikai Ma,Qingyun Zhang,Rui Li,Shuzhen Liu,Guohua Yu
DOI: https://doi.org/10.2147/ott.s428745
IF: 4
2024-02-14
OncoTargets and Therapy
Abstract:Wenjuan Meng, 1, &ast Qingxia Guo, 2 Gaoyan Tang, 1 Guiyan Han, 3 Guikai Ma, 1 Qingyun Zhang, 1 Rui Li, 1 Shuzhen Liu, 1, &ast Guohua Yu 1 1 Department of Oncology, Weifang People's Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, Shandong, 261041, People's Republic of China; 2 Department of Oncology, Junan People's Hospital, Junan, Shandong, 276600, People's Republic of China; 3 Department of Pathology, Weifang People's Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, Shandong, 261041, People's Republic of China &astThese authors contributed equally to this work Correspondence: Guohua Yu, Department of Oncology, Weifang People's Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, Shandong, 261041, People's Republic of China, Email Thyroid metastases secondary to triple-negative breast cancer are sporadic. Diagnosis usually requires fine needle aspiration biopsy (FNAB) and immunohistochemistry. There are no treatment guidelines for this type of cancer, and to date, reports of chemotherapy combined with immunotherapy in thyroid metastases are very rare. Here, we first report the effectiveness of anti-PD-1 inhibitor in combination with chemotherapy for the treatment of metastatic thyroid cancer secondary to advanced triple-negative breast cancer with high expression of programmed cell death ligand 1 (PD-L1). Following six cycles of albumin paclitaxel (400mg d1/21 days) plus PD-1 antibody inhibitor (Sindilizumab 200mg d1/21 days), the patient experienced significant relief of neck swelling and obstructive feeding, both the thyroid metastases and the right breast lesion regressed completely following six cycles of treatment. Chemotherapy combined with immunotherapy may provide a new direction for unresectable advanced thyroid metastases. Keywords: thyroid metastases, triple-negative breast cancer, albumin paclitaxel, anti-PD-1 inhibitor, effectiveness A 54-year-old middle-aged woman presented to our hospital with a swollen and uncomfortable neck with a feeling of obstruction to eating. One week ago, she went to a local hospital where ultrasound of the neck showed diffuse enlargement of the thyroid gland, bilateral enlarged lymph nodes in the neck. The lymph nodes in the supraclavicular fossa were enlarged bilaterally. Ultrasound-guided fine-needle aspiration biopsy of the thyroid mass showed: invasive ductal carcinoma of mammary origin (Figure 1A), grade II, immunohistochemistry: ER (-), PR (-), GATA-3 (+), P120 (+), Ecad (+), TTF-1 (-), CK7 (+), CK20 (-), Villin (-), CK5/6 (-). PD-L1 expression was assessed by immunohistochemistry using a rabbit monoclonal anti-human PD-L1 antibody (Ventana SP142); the percentage of positive tumour cells was 26–49% (Figure 1B). Figure 1 (A) HE staining of the thyroid mass showed invasive ductal carcinoma of mammary origin. (B) IHC examination revealed the thyroid mass was positive for PD-L1. (C) Breast MR showed a right breast nodule (red arrow), BI-RADS category 4 (1.1cm x 0.8cm x 0.8cm). (D) CT of the neck, chest and abdomen showed primary breast cancer with thyroid metastases (red arrow meant metastatic lesion). After admission, thyroid function tests: thyroglobulin autoantibodies (A-TG) 20.20 IU/mL (0–60); free triiodothyronine (FT3) 8.36 pmol/L (3.5–6.5); free thyroxine (FT4) 36.15 pmol/L (11.5–22.7); thyrotropin (TSH) 0.01 uIU/mL (0.55–4.78); thyroid peroxidase autoantibodies (A-TPO) C p.M1628T h -Abstract Truncated-
oncology,biotechnology & applied microbiology